Andrographis Paniculata: A Potential Shield Against Pneumonia in Early COVID-19

Written By Hiroshi Wald

Study Overview: A focused retrospective cohort study examining Andrographis Paniculata's impact on early-stage COVID-19 patients.

  • Participants: Patients aged 15-60 years with laboratory-confirmed COVID-19.

  • Treatment Protocol: Utilization of AP-extract or crude-AP, emphasizing andrographolide content.

  • Key Finding: A significant reduction in pneumonia incidence among AP-treated patients compared to non-treated groups.

  • Safety Assessment: Reports of mild adverse effects, confirming the safety of AP in treatment.

  • Implications: AP's efficacy in reducing pneumonia risk positions it as a promising, safe option for early COVID-19 intervention.

These insights highlight Andrographis Paniculata's potential role in managing early COVID-19, particularly in preventing pneumonia, underlining its importance in current therapeutic strategies.

Source: https://www.medrxiv.org/content/10.1101/2023.03.15.23287287v1

Hiroshi Wald
Previous

Exploring Andrographis Paniculata in Long-Haul COVID Management: Additional Research on Nutraceuticals and Botanicals
Next

Unlocking Andrographis Paniculata's Anti-COVID-19 Potential: A Molecular Perspective